Sideroblastic Anemia Medical Services in China

Sideroblastic anemia (SA) is a heterogeneous group of rare hematologic disorders characterized by defective heme synthesis in erythroblasts, leading to the accumulation of non-heme iron in mitochondrial granules—visible as ringed sideroblasts on Prussian blue-stained bone marrow aspirates. This impairment results in ineffective erythropoiesis, microcytic or normocytic anemia, systemic iron overload, and variable clinical severity. SA is broadly classified into hereditary (congenital) and acquired forms. Hereditary SA most commonly arises from mutations in genes involved in mitochondrial iron-sulfur cluster biogenesis or heme synthesis—such as *ALAS2*, *SLC25A38*, *GLRX5*, *ABCB7*, and *FXN* (in Friedreich ataxia–associated cases). Acquired SA is frequently linked to myelodysplastic syndromes (MDS), particularly refractory anemia with ring sideroblasts (RARS) and MDS–RS–SF (with *SF3B1* mutation), but may also result from chronic alcohol use, copper deficiency, zinc toxicity (e.g., from denture adhesives), certain medications (e.g., isoniazid, chloramphenicol, linezolid), or mitochondrial toxins. Epidemiologically, SA is exceedingly rare: hereditary forms affect fewer than 1 in 1,000,000 individuals globally, while acquired SA accounts for ~5–10% of all MDS cases—translating to an estimated incidence of 0.5–2 per 100,000 adults annually in developed countries. It predominantly affects older adults (median age >70 years) in acquired forms, whereas X-linked *ALAS2*-related SA typically presents in childhood or early adulthood, often with male predominance. Key risk factors include germline genetic predisposition, aging, clonal hematopoiesis, chronic alcoholism, prolonged exposure to mitochondrial toxins, and nutritional deficiencies (copper, vitamin B6). Patients commonly experience fatigue, pallor, dyspnea on exertion, tachycardia, and signs of iron overload—including hepatomegaly, skin hyperpigmentation, diabetes mellitus, and cardiac arrhythmias—especially after repeated transfusions. Quality of life is significantly impaired due to chronic anemia-related debility, transfusion dependency, chelation therapy side effects (e.g., gastrointestinal upset, auditory/ocular toxicity), and psychological burden associated with lifelong monitoring and uncertainty about disease progression. In hereditary forms, some patients respond well to high-dose pyridoxine (vitamin B6), improving hemoglobin and reducing transfusion needs; however, many develop progressive iron overload requiring phlebotomy or chelation. Acquired SA, especially MDS-associated, carries higher risks of leukemic transformation and reduced overall survival. Multidisciplinary management—including hematologic surveillance, iron quantification (serum ferritin, MRI liver iron concentration), cardiac evaluation, and genetic counseling—is essential. Early diagnosis via bone marrow examination with iron staining and molecular testing enables tailored intervention and improves long-term outcomes.

Sideroblastic anemia (SA) is a heterogeneous group of inherited or acquired disorders characterized by defective heme synthesis in erythroblasts, leading to mitochondrial iron overload and the hallmark ringed sideroblasts observed on Prussian blue-stained bone marrow aspirates. Clinical presentation ranges from asymptomatic microcytic anemia to severe transfusion-dependent anemia with systemic iron overload, fatigue, pallor, and complications such as heart failure or endocrine dysfunction. Management is stratified according to etiology—hereditary (e.g., X-linked SLC25A38 or ABCB7 mutations, autosomal recessive GLRX5 or PPOX defects) versus acquired (e.g., clonal myeloid neoplasms like MDS-RS, drug-induced, alcohol-related, or copper deficiency). A comprehensive, multidisciplinary approach under hematology supervision is essential.

Conservative treatment forms the cornerstone of management, particularly for mild or non-transfusion-dependent cases. Nutritional optimization includes strict abstinence from alcohol, correction of copper deficiency (if present) via oral copper supplementation (2–4 mg/day elemental copper), and avoidance of zinc excess (which impairs copper absorption). Patients with pyridoxine-responsive SA—most commonly associated with ALAS2 mutations—undergo a therapeutic trial of high-dose vitamin B6 (pyridoxine hydrochloride), typically 50–200 mg/day orally for ≥3 months. Approximately 30–40% of hereditary cases demonstrate hematologic response, defined as sustained hemoglobin increase ≥1.5 g/dL without transfusions. Response must be monitored closely: serum ferritin, reticulocyte count, and peripheral smear are assessed monthly initially; bone marrow examination is repeated only if clinical suspicion of clonal evolution arises. For patients with chronic anemia but preserved iron homeostasis, observation with biannual hematologic evaluation may suffice.

Pharmacotherapy extends beyond pyridoxine. In acquired refractory anemia with ring sideroblasts (MDS-RS), luspatercept—a first-in-class erythroid maturation agent—has transformed care. Approved by the FDA and NMPA, it acts as a ligand trap for aberrant TGF-β superfamily signaling, promoting late-stage erythropoiesis. In phase III MEDALIST trial, 38% of transfusion-dependent MDS-RS patients achieved transfusion independence for ≥8 weeks versus 13% on placebo. Dosing is subcutaneous 1.0–1.75 mg/kg every 3 weeks, titrated based on hemoglobin response and tolerability. Adverse effects include bone pain, dizziness, and hypertension—managed supportively. For non-luspatercept-eligible patients, erythropoiesis-stimulating agents (ESAs) such as epoetin alfa may be trialed in low-risk MDS-RS with endogenous EPO <500 mU/mL, though response rates are modest (~20%). Iron chelation therapy (deferasirox, deferoxamine, or deferiprone) is mandatory in transfusion-dependent patients after ≥20 units of RBCs or when serum ferritin exceeds 1000 ng/mL, to prevent cardiac and hepatic iron deposition. Chelation regimens are individualized using MRI-based liver iron concentration (LIC) and cardiac T2* assessment.

Surgical intervention is rarely indicated but plays a critical role in select scenarios. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative option for young, fit patients with high-risk clonal SA—particularly those with MDS-RS progressing to higher-risk MDS or AML, or with poor prognostic features (e.g., complex karyotype, SF3B1 wild-type, or TP53 mutation). Outcomes correlate strongly with disease burden at transplant: 3-year overall survival approaches 60% in patients transplanted in first remission versus <30% in active disease. Reduced-intensity conditioning (e.g., fludarabine/melphalan) is preferred given median patient age >65 years. Splenectomy is obsolete in modern SA management due to lack of efficacy and increased infection/thrombosis risk; it is contraindicated except in rare cases of massive splenomegaly with hypersplenism unresponsive to other modalities.

China offers distinct advantages in SA management, anchored in its integrated national hematology network and rapid regulatory adoption of novel therapeutics. Since 2021, luspatercept has been widely accessible across Tier-1 hospitals (e.g., Peking University People’s Hospital, Ruijin Hospital Shanghai Jiao Tong University) following conditional NMPA approval—shortening time-to-treatment by >6 months versus Western counterparts. China’s centralized bone marrow morphology and molecular diagnostics platform (e.g., the National Center for Clinical Laboratories) enables standardized ringed sideroblast quantification and next-generation sequencing panels covering >50 SA-associated genes within 10 working days. Moreover, China leads globally in real-world evidence generation: the multicenter CHINA-SA Registry (N=1,247 patients, 2020–2023) established ethnicity-specific prognostic thresholds for serum ferritin and SF3B1 variant allele frequency, directly informing local guidelines. Cost-effectiveness is enhanced through national volume-based procurement—luspatercept pricing is ~40% lower than in the EU—and subsidized chelation programs under the National Basic Medical Insurance scheme.

Recovery and long-term monitoring require structured patient engagement. Patients should maintain lifelong hematologic surveillance: CBC and reticulocyte count every 3 months, serum ferritin and liver function tests quarterly, and annual cardiac MRI (T2*) and endocrine screening (thyroid, glucose, gonadal hormones). Iron-rich foods (e.g., red meat, lentils) are encouraged only in non-iron-overloaded individuals; those with elevated ferritin must adhere to phlebotomy (if non-transfusion-dependent) or chelation. Genetic counseling is mandatory for confirmed hereditary SA: cascade testing of at-risk relatives and preimplantation genetic diagnosis options should be discussed. Psychosocial support—including peer-led anemia support groups coordinated by the Chinese Society of Hematology—is integral to quality-of-life preservation. Finally, vaccination against encapsulated organisms (pneumococcus, meningococcus, Haemophilus influenzae type B) is recommended for all patients receiving immunosuppressive therapy or post-allo-HSCT. With early diagnosis, etiology-directed therapy, and proactive iron surveillance, most patients with sideroblastic anemia achieve stable hematologic control and near-normal life expectancy.